Moradi Jale, Mosavari Nader, Ebrahimi Mahmoud, Arefpajohi Reza, Tebianian Majid
Department of TB, Razi Vaccine and Serum Research Institute, Karaj, Iran.
Osong Public Health Res Perspect. 2015 Feb;6(1):34-8. doi: 10.1016/j.phrp.2014.12.002. Epub 2014 Dec 24.
OBJECTIVES: Tuberculosis (TB) is the leading infectious disease in the developing world. Delayed-type hypersensitivity skin test diagnoses TB using tuberculin purified protein derivative (PPD), but this test is incapable of distinguishing Mycobacterium tuberculosis (MTB) infection from bacillus Calmette-Guérin (BCG) vaccination or an infection caused by nontuberculous mycobacteria (NTM). This study was performed to evaluate the use of recombinant early secretory antigenic target 6 (rESAT-6), a secretory protein found only in MTB, Mycobacterium bovis, and few other mycobacterial species, as a skin marker for MTB in guinea pigs. METHODS: We prepared recombinant MTB ESAT-6 and evaluated its use as a specific antigen for MTB in guinea pigs. RESULTS: Our results show that the purified MTB rESAT-6 antigen is capable of inducing a positive reaction only in guinea pigs sensitized to MTB. No such reaction was observed in the animals sensitized to M. bovis, BCG vaccination, or NTM (Mycobacterium avium). CONCLUSION: Our study results confirm that the ESAT-6 antigen is more specific to MTB infection than PPD and could be used in more specific skin tests for detection of MTB in large animals and in humans.
目的:结核病是发展中国家主要的传染病。迟发型超敏反应皮肤试验使用结核菌素纯蛋白衍生物(PPD)诊断结核病,但该试验无法区分结核分枝杆菌(MTB)感染与卡介苗(BCG)接种或非结核分枝杆菌(NTM)引起的感染。本研究旨在评估重组早期分泌性抗原靶标6(rESAT-6)作为豚鼠MTB皮肤标志物的用途,rESAT-6是一种仅在MTB、牛分枝杆菌和其他少数分枝杆菌物种中发现的分泌蛋白。 方法:我们制备了重组MTB ESAT-6,并评估了其作为豚鼠MTB特异性抗原的用途。 结果:我们的结果表明,纯化的MTB rESAT-6抗原仅能在对MTB致敏的豚鼠中诱导阳性反应。在对牛分枝杆菌致敏、接种BCG或NTM(鸟分枝杆菌)的动物中未观察到此类反应。 结论:我们的研究结果证实,ESAT-6抗原对MTB感染的特异性高于PPD,可用于更特异性的皮肤试验,以检测大型动物和人类中的MTB。
Osong Public Health Res Perspect. 2015-2
Kekkaku. 2008-9
Int J Tuberc Lung Dis. 2010-4
Tuberculosis (Edinb). 2006-9
Iran J Vet Res. 2018
Protein Expr Purif. 2013-12
Tuberculosis (Edinb). 2012-3
Emerg Infect Dis. 2007-4
Clin Microbiol Infect. 2004-5